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Aurora kinase A inhibition reverses the Warburg
effect and elicits unique metabolic vulnerabilities in
glioblastoma
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Trang T. T. Nguyen 1, Enyuan Shang2, Chang Shu1, Sungsoo Kim1, Angeliki Mela1, Nelson Humala3,
Aayushi Mahajan3, Hee Won Yang 1, Hasan Orhan Akman4, Catarina M. Quinzii4, Guoan Zhang5,
Mike-Andrew Westhoff6, Georg Karpel-Massler7, Jeffrey N. Bruce 3, Peter Canoll1 & Markus D. Siegelin

Aurora kinase A (AURKA) has emerged as a drug target for glioblastoma (GBM). However,
resistance to therapy remains a critical issue. By integration of transcriptome, chromatin
immunoprecipitation sequencing (CHIP-seq), Assay for Transposase-Accessible Chromatin
sequencing (ATAC-seq), proteomic and metabolite screening followed by carbon tracing and
extracellular ﬂux analyses we show that genetic and pharmacological AURKA inhibition
elicits metabolic reprogramming mediated by inhibition of MYC targets and concomitant
activation of Peroxisome Proliferator Activated Receptor Alpha (PPARA) signaling. While
glycolysis is suppressed by AURKA inhibition, we note an increase in the oxygen consumption rate fueled by enhanced fatty acid oxidation (FAO), which was accompanied by an
increase of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α).
Combining AURKA inhibitors with inhibitors of FAO extends overall survival in orthotopic
GBM PDX models. Taken together, these data suggest that simultaneous targeting of oxidative metabolism and AURKAi might be a potential novel therapy against recalcitrant
malignancies.
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lioblastoma WHO grade IV (GBM) is the most common
primary brain tumor in adults and thus far very limited
therapeutic options for this recalcitrant malignancy have
been identiﬁed with essentially no durable response, resulting in a
grim survival of only 12−15 months1–6. Key contributing factors
of the resistance to therapy are the heterogeneity of these tumors,
diffuse and inﬁltrative growth, the presence of the blood-brain
barrier, and likely the plasticity of these tumors to reactivate
alternate survival pathways. For the most part, glioblastomas
consume glucose and utilize its carbons to facilitate biosynthesis
of nucleotides and lipids to enable growth, while oxidative
metabolism is relatively suppressed (Warburg-effect)7,8. The
recent literature highlights a role for the transcription factor, cMyc, which is known to facilitate several aspects of this pathway
by driving the expression of key glycolytic and anabolic enzymes9.
Aurora kinases are important for the proliferation and growth
of solid tumors, including glioblastomas. They are phosphorylating several substrates that are directly involved in cell cycle
regulation. Several members have been described and Aurora
kinase A has been identiﬁed as a target for glioblastoma therapy,
especially because speciﬁc inhibitors exist (alisertib, MLN8237)
that have shown limited single-agent efﬁcacy in orthotopic GBM
model systems. Importantly, clinical trials have been initiated
with these compounds as well10–12. For this reason, a better
understanding about the response and resistance of these compounds is warranted to arrive at more efﬁcacious treatments.
c-Myc (MYC) is an oncogenic transcription factor that facilitates tumor proliferation in part through the regulation of
metabolism. It carries a short half-life, and its stability is regulated
by two interdependent phosphorylation sites, Serine 62 (S62) and
Threonine 58 (T58). The phosphorylation at S62, which is
facilitated by ERK, precedes the one at T58, which is mediated by
GSK3β and subjects c-Myc to ubiquitin conjugation via the
ubiquitin ligase FBXW713.
In this study, we investigated how Aurora kinase A inhibition
affects glioblastoma cell metabolism and how the derived
knowledge from these studies can be leveraged for the design of
drug combination therapies. We made the unexpected and
important ﬁnding that the response to Aurora kinase A inhibitors
depends on glycolysis and that tumor cells with an oxidative
metabolic phenotype will be more resistant to Aurora kinase A
inhibitor treatment. Moreover, in a manner dependent on the
transcription factors c-MYC and PGC1α treatment with Aurora
kinase A inhibitors renders GBM cells highly oxidative and
dependent on fatty acid oxidation that in turn mediates them to
be susceptible to inhibitors of FAO in vitro and in vivo.
Results
Aurora kinase A regulates proliferation and glycolysis through
the oncogene, c-Myc. Following proteomic analysis, we found
that SF188 GBM cells treated with alisertib, a clinically validated
highly speciﬁc AURKA inhibitor, displayed substantial downregulation of the c-Myc protein (Fig. 1a), a master regulator of
cell proliferation and metabolism9. We chose c-Myc over other
targets due to its substantial role in tumorigenesis and its
implication in aerobic glycolysis. A complete list of all the targets
is provided in the source data ﬁle. Subsequently, we conﬁrmed
this observation by performing protein capillary electrophoresis
in SF188 and GBM22 PDX cells (Fig. 1b). Treatment with alisertib abolished autophosphorylation of Aurora kinase A at
Thr288 (T288) accompanied by a decrease in c-Myc protein levels
(Fig. 1b and Fig. S1a). Consistently, alisertib reduced c-Myc
protein levels in a dose-dependent manner as early as 1 h in these
model systems (Fig. S1b, c). We also conﬁrmed that alisertib
revealed anti-glioma activity in the GBM22 orthotopic PDX
2

model, revealing smaller tumors following treatment with the
Aurora kinase A inhibitor (Fig. S1d, e). In addition, we also noted
that c-Myc protein levels substantially decreased following
treatment with alisertib in an orthotopic murine GBM model
(Fig. S1f−i). Consistently, we found reduced phosphorylation of
Aurora kinase A following treatment with alisertib (Fig. S1f, g).
Next, we genetically targeted AURKA by using siRNA, shRNA, or
CRISPR/Cas9 in GBM cells (Fig. 1c). Resembling the alisertib
treatment, we noted a reduction in c-Myc protein levels in
AURKA knock down and knock out cells. To conﬁrm that c-Myc
is the actual effector of Aurora kinase A-mediated inhibition of
proliferation, we silenced c-Myc by two speciﬁc siRNA. Silencing
of c-Myc resulted in a signiﬁcant reduction of the effect of
AURKA inhibition on cellular viability in SF188 and GBM22 cells
(Fig. 1d), suggesting that c-Myc is a key mediator in this context.
Similarly, when c-Myc was silenced alisertib lost its ability to
further elicit induction of apoptosis in GBM cells (Fig. S2a, b).
Consistently, dual silencing of c-Myc and AURKA did neither
yield further enhancement of apoptosis nor reduction in cellular
viability as compared to silencing of each gene on its own (Fig.
S2c−e). Next, we determined whether over-expression of c-Myc
could partially attenuate the effects of alisertib-mediated reduction in cellular viability in GBM cells. To this end, we utilized an
adenovirus encoding for c-Myc. Indeed, SF188 and GBM22 cells
that over-expressed c-Myc were slightly less sensitive to alisertib
mediated reduction in viability (Fig. 1e). In summary, these
results conﬁrm the notion that loss of c-Myc is functionally
involved in the reduction of viability elicited by Aurora kinase A
inhibition.
Next, we investigated how Aurora kinase A inhibition leads to
a reduction in c-Myc protein levels. The c-Myc protein levels are
known to be heavily regulated by the proteasome9,14–16. Hence,
treatment with alisertib did not reduce c-Myc mRNA levels (Fig.
S2f). Next, we assessed whether Aurora kinase A interacts with
c-Myc. To this end, we performed co-immunoprecipitation
analysis and found that c-Myc bound to Aurora kinase A in
both SF188 and GBM22 cells (Fig. 1f). This was also conﬁrmed in
293T cells by co-transfection of Flag-tagged c-Myc and HAtagged AURKA (Fig. S3a). Similarly, proximity ligation assay
demonstrated an interaction between c-Myc and Aurora kinase A
in both SF188 and GBM22 cells (Fig. S3b−e). Next, we assessed
whether alisertib was capable to disrupt the interaction between
c-Myc and Aurora kinase A. To this purpose, SF188 GBM cells
were treated with increasing dosages of alisertib, followed by
c-Myc immunoprecipitation. While the vehicle-treated cells
showed a strong interaction between c-Myc and Aurora kinase
A, higher concentrations of the drug elicited a disruption of the
complex (Fig. S3f, g). Furthermore, we probed these lysates for
GSK3β. We found that the relative binding ratio between GSK3β
and Aurora kinase A to c-Myc increased following alisertib
treatment in a concentration-dependent manner, suggesting that
alisertib favors the binding of GSK3β to c-Myc over Aurora
kinase A, in keeping with the overall reduction of c-Myc protein
levels (Fig. S3f, g). Akin to the co-IP assay, the proximity ligation
assay conﬁrmed that alisertib disrupted the interaction between
Aurora kinase A and c-Myc (Fig. S3h, i). Given that direct
silencing of Aurora kinase A leads to a suppression of c-Myc
protein levels, it appears likely that Aurora kinase A acts as a
chaperone to protect c-Myc from proteasomal degradation. To
address this hypothesis, we utilized a two-pronged strategy. First,
we treated SF188 cells with alisertib in the presence or absence of
the proteasomal inhibitor, MG132. As expected, we found that
MG132 substantially reversed alisertib-mediated suppression of
c-Myc (Fig. 1g). Second, we conducted a cycloheximide block
experiment. Consistently, the stability of c-Myc was signiﬁcantly
reduced in the presence of alisertib (Fig. 1h, i and Fig. S3j). These
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two observations narrow the range and strongly favor a
mechanism that involves the proteasome following Aurora kinase
A inhibition. Classically, c-Myc is phosphorylated prior to its
degradation and there are two sites that have been reported to
orchestrate this, S62 and T5815,16. The phosphorylation at S62
precedes the one at T58, which is mediated by GSK3β and
subjects c-Myc to ubiquitin conjugation. In agreement with this
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general concept, alisertib enhanced the phosphorylation at S62
and T58, respectively, which occurred as early as one hour
following exposure to the drug compound, indicating that these
two posttranslational modiﬁcations are early events that precede
c-Myc degradation (Fig. 1j, k). To further elucidate the role of
these posttranslational modiﬁcations we utilized a T58A nonphosphorylatable c-Myc mutant. Ectopic expression of the T58A
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Fig. 1 Blocking AURKA stalls the proliferation of GBM by reducing glycolysis in a c-Myc dependent manner. a Volcano plot of reverse-phase-proteinarray (RPPA) data shows a reduced expression of c-Myc (red dot) in SF188 GBM cells treated with 100 nM alisertib for 24 h (n = 3 independent samples).
FC: fold change. b Protein capillary electrophoresis of SF188 and GBM22 cells treated with the indicated concentrations of alisertib for 24 h. Vinculin is used
as a loading control. c SF188 was transfected with non-targeting (siNT) or AURKA speciﬁc siRNA (siAURKA) or transduced with shARKA (shRNA) or
sgAURKA (sgRNA) and the whole-cell protein lysates were subjected to protein capillary electrophoresis. d SF188 and GBM22 cells were transfected with
non-targeting (siNT) or two speciﬁc siRNAs targeting Myc, treated with increasing concentrations of alisertib for 72 h, and cellular viability was analyzed
(n = 4 independent samples). IC50 in µM range. e SF188 and GBM22 cells were infected with empty vector or c-Myc adenovirus and treated with
increasing concentration of alisertib for 72 h, and cellular viability was analyzed (n = 4 independent samples). IC50 in µM range. f SF188 and GBM22 cell
lysates were immunoprecipitated with IgG or c-Myc antibody and analyzed by standard western blot for the indicated antibodies. Input: cell lysate loading
control. IgG: negative control. g SF188 cells were treated with DMSO or alisertib in the presence or absence of 5 µM MG132 and the whole-cell lysates
were subjected to protein capillary electrophoresis for the indicated proteins. For h, i SF188 cells were treated with DMSO or alisertib in the presence or
absence of 10 µg/mL cycloheximide (CHX) and the whole-cell lysates were subjected to protein capillary electrophoresis. Quantiﬁcation of c-Myc protein
level is shown in (i) (n = 3 independent samples). For j, k protein capillary electrophoresis for the indicated proteins of SF188 and GBM22 cells treated with
DMSO or alisertib for different time points. Quantiﬁcation of protein level is shown in (k) (n = 2 independent samples). l SF188 cells were transfected with
c-Myc-WT or c-Myc mutant (T58A), treated with the indicated concentrations of alisertib for 24 h, and analyzed by protein capillary electrophoresis for
the indicated proteins. m GBM22-Myc-WT or GBM22-T58A-Myc cells were implanted in the right striatum of nude mice. Two groups were randomly
assigned: vehicle and alisertib after seven days of the implantation. Mice were treated three times per week and animal survival is provided (Kaplan
−Meier-curve): GBM22-T58A-Myc-vehicle: 34d, GBM22-T58A-Myc-alisertib: 27d; GBM22-Myc-OE-vehicle: 38d, GBM22-Myc-OE-alisertib: 50d. The
log-rank test was used to assess statistical signiﬁcance (n = 5 independent samples) (*p = 0.0127, n.s not signiﬁcant). n SF188 and GBM22 cells were
transfected with non-targeting siNT or siAURKA in the presence or absence of 2 µM CHIR-908014 (CHIR) for 24 h and were subjected to protein capillary
electrophoresis for the indicated proteins. o SF188 and GBM22 cells were transfected with HA-EV, HA-Aurora A-WT, HA-Aurora A-D274N and were
subjected to protein capillary electrophoresis for the indicated proteins. Statistical signiﬁcance was assessed by two-tailed student’s t-test in (m). Data are
shown as mean ± SD in (d, e, i, k). Source data are provided as a Source Data ﬁle.

c-Myc mutant rendered GBM cells resistant towards alisertibmediated c-Myc degradation (Fig. 1l and Fig. S3k). The
substantial impact on c-Myc stability conferred by the
phospho-mutant (T58A) led us to hypothesize that c-Myc likely
has a central role in mediating the response and resistance to
alisertib. To this end, we transduced GBM22 cells with lentiviral
particles encoding c-Myc T58A and c-Myc wild-type (Fig. S3l).
Stably transduced GBM22 cells were implanted in the right
striatum. Upon tumor formation, animals were either treated
with vehicle or alisertib until the animals met the endpoint. As
anticipated, host animals carrying orthotopically implanted
GBM22 cells expressing the T58A mutated c-Myc were resistant
towards alisertib treatment, whereas animals carrying wild-type cMyc orthotopic xenografts were sensitive to the drug and revealed
an extended overall survival (Fig. 1m).
To conﬁrm the involvement of GSK3β in c-Myc-mediated
degradation, we interfered with the function of this kinase.
Indeed, the GSK3β blocker, CHIR-908014, prevented alisertibmediated degradation of c-Myc (Fig. 1n and Fig. S4a). In
alignment with this ﬁnding, silencing of AURKA or pharmacological inhibition reduced the phosphorylation of GSK3β,
rendering this kinase more active, resulting in enhanced
phosphorylation and degradation of c-Myc (Fig. 1n and Fig.
S4a, b). In addition to pharmacological inhibition of GSK3β, we
silenced this gene, using siRNA. In line with the pharmacological
inhibition, genetic interference with GSK3β reduced alisertibmediated reduction of c-Myc levels (Fig. S4c, d). We wondered
whether AURKA would bind to GSK3β to block its function.
Indeed, co-immunoprecipitation studies indicated that GSK3β
and Aurora kinase A formed a complex in SF188 GBM cells (Fig.
S4e). While a direct binding between these proteins has been
shown earlier17, the interaction of the two kinases in GBM
models and its impact on c-Myc are unique. Further conﬁrmation
of the GSK3β and Aurora kinase A complex was obtained by
utilizing the proximity ligation assay, which conﬁrmed the
ﬁndings in both GBM22 and SF188 cells (Fig. S4f−i). Next, we
wondered whether AURKA could simultaneously interact with
both c-Myc and GSK3β. To this end, we transfected SF188 and
GBM22 cells with HA-tagged AURKA and performed co-IP. We
found that indeed both c-Myc and GSK3β are bound to Aurora
4

kinase A (Fig. S5a). To further clarify this interaction and the role
of Aurora kinase A we performed an additional co-IP analysis in
which three plasmids (untagged-AURKA, Flag-GSK3β, and HAc-MYC) were simultaneously transfected. The plasmid encoding
for Aurora kinase A was used at three different dosages to
demonstrate that Aurora kinase A disrupts the interaction
between c-Myc and GSK3β and thereby inhibits the phosphorylation of c-Myc at T58 by GSK3β (Fig. S5b). To extent these
ﬁndings related to MYC phosphorylation/degradation further in
the context of glioblastoma cells, we have generated a kinase-dead
mutant of Aurora kinase A (D274N). When compared to wildtype Aurora kinase A the kinase-dead mutant revealed reduced
ability to phosphorylate GSK3β at serine 9 (Fig. S5c). Consistently, we observed that only the wild-type, but not the kinasedead mutant Aurora kinase A was able to increase c-Myc protein
levels in both SF188 and GBM22 cells (Fig. 1o). Thus, these
observations support the idea that Aurora kinase A regulates the
phosphorylation of c-Myc by GSK3β in a kinase-dependent
manner. In summary, AURKA stabilizes the c-Myc protein and
antagonizes GSK3β mediated phosphorylation of c-Myc and its
subsequent degradation mediated by the proteasome.
Aurora kinase A drives GBM proliferation through activation
of glycolysis in GBM cells. Based on a high throughput drug
screen18 we made the intriguing observation that interference
with Aurora kinase A and the respiratory chain may be synthetically lethal, suggesting that blockage of Aurora kinase A signaling may activate oxidative metabolism and that this, in turn,
may be used by GBM cells to acquire resistance. Conversely,
while Aurora kinase A might activate respiration it likely would
reduce glycolysis. Since c-Myc is a known master regulator of the
Warburg-effect, controlling the expression of several key glycolytic genes, it was tempting to speculate whether Aurora kinase A
inhibition would reduce the proliferation of GBM cells in a
manner dependent on glycolysis, which is controlled by c-Myc.
To determine whether alisertib reduces cellular viability through
regulation of glycolysis GBM cells were grown in galactosecontaining medium, which reduces glycolytic ﬂux and forces cells
to depend on mitochondrial oxidative phosphorylation for energy
production (Leloir pathway). The GBM cells grown in glucose are
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more sensitive to alisertib treatment or genetic interference
(CRISPR/Cas9) with AURKA compared to the ones grown in
galactose (Fig. 2a, b).
Next, we determined whether Aurora kinase A inhibition
suppresses glycolysis. To this purpose, we used extracellular ﬂux
analysis (Seahorse analyzer) in the context of a glycolytic stress
assay. Cells are initially starved, exposed to glucose followed by
injection of oligomycin to exacerbate the highest glycolytic
activity. The assay is completed with 2-DG to block glycolysis. In
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this setting, we noted that alisertib suppressed the activity of
glycolysis in both SF188 and GBM22 PDX cells (Fig. 2c, d). To
account for speciﬁcity, we utilized an Aurora kinase A speciﬁc
siRNA and conducted the glycolytic stress assay. Similarly, to the
drug compound, silencing of Aurora kinase A diminished
glycolytic activity, suggesting that Aurora kinase A regulates
glycolysis in GBM model systems (Fig. S6a). Next, we determined
the impact of Aurora kinase A on key glycolytic transporters
(SLC2A1) and enzymes (HK2, LDHA), some of which are
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Fig. 2 Blocking AURKA stalls GBM growth by reducing glycolysis. a SF188 and GBM22 cells were cultured in galactose or glucose media for a week,
treated with increasing concentrations of alisertib for 72 h, and cellular viability was analyzed (n = 4 independent samples). b SF188 GBM cells either
transduced with a non-targeting (sgNT) or two different AURKA (sgAURKA) sgRNAs were cultured in galactose or glucose media for a week and treated
with increasing concentration of alisertib. Cellular growth over time was determined (n = 4 independent samples). For c, d SF188 and GBM22 cells were
treated with DMSO or alisertib and analyzed in the context of a glycolysis stress assay on a Seahorse XFe24 extracellular ﬂux analyzer. Extracellular
acidiﬁcation rate (ECAR) is recorded at baseline, after injection of Glucose (G), Oligomycin (OM), and 2-DG. Quantiﬁcation of glycolysis is shown in (d)
(n = 5 independent samples). e Real-time PCR analysis of the mRNA level of genes related to glycolysis in SF188 and GBM22 cells treated with DMSO or
alisertib for 24 h (n = 8 in SF188 + DMSO and GBM22 + DMSO, n = 4 in SF188 + Ali 0.1 μM and GBM22 + Ali 1 μM, independent samples). (HK2: SF188
***p = 0.0002, GBM22: ***p = 0.0003; **p = 0.0082, ****p < 0.0001). 18S: internal control. FC: fold change. f SF188 and GBM22 cells were treated with
DMSO or alisertib for 24 h and the whole-cell protein lysates were subjected to protein capillary electrophoresis. Vinculin is used as a loading control. g
SF188 cells were transfected with non-targeting siRNA or speciﬁc AURKA siRNAs (single or pool) and the whole-cell lysates were analyzed by protein
capillary electrophoresis for the indicated proteins. h Real-time PCR analysis of the mRNA level of genes related to glycolysis in SF188 transfected with
non-targeting siRNA or speciﬁc siRNA targeting AURKA (n = 4 independent samples) (*p = 0.0179, ***p = 0.0001). i Shown are the ATP levels measured
by polar LC/MS of SF188 cells treated with DMSO or 100 nM alisertib (n = 5 independent samples) (*p = 0.0221). For j, k SF188 and GBM22 cells were
transfected with non-targeting or speciﬁc siRNA targeting AURKA and were analyzed in the context of a glycolysis stress assay on a Seahorse XFe24
extracellular ﬂux analyzer. The graphs show glycolysis level in (j) (SF188: n = 2 in siNT, n = 3 in siAURKA; GBM22: n = 3 independent samples)
(**p = 0.0032) or OCR/ECAR levels in (k) (SF188: n = 3; GBM22: n = 3 in siNT, n = 2 in siAURKA independent samples) (***p = 0.0001). l SF188 cells
were transfected with c-Myc-WT and c-Myc mutant (T58A), treated with increasing concentrations of alisertib for 24 h, and the whole-cell lysates were
analyzed by protein capillary electrophoresis. m SF188 cells were transfected with c-Myc-WT and c-Myc mutant (T58A), treated with 50 nM alisertib for
24 h, and analyzed on a Seahorse XFe24 extracellular ﬂux analyzer. Shown is the quantiﬁcation of ECAR level (n = 5 independent samples) (**p = 0.0073,
n.s not signiﬁcant). n SF188 and GBM22 cells were treated with alisertib for 24 h and were subjected to CHIP with an IgG as a negative control or a c-Myc
speciﬁc antibody. The HK2 region was ampliﬁed by PCR (n = 3 independent samples). Statistical signiﬁcance was assessed by a two-tailed student’s t-test.
Data are shown as mean ± SD in (a−e, h−k, m, n). Source data are provided as a Source Data ﬁle.

upregulated in glioblastoma as compared to normal brain tissue
(Fig. S6b). Following treatment with alisertib or speciﬁc silencing
of Aurora kinase A we detected a signiﬁcant suppression of both
mRNA and protein levels of GLUT1, HK2, and LDHA in SF188
and GBM22 cells (Fig. 2e–h). We also conﬁrmed the downregulation of these transcripts in an orthotopic GBM PDX model
that we used earlier for the conﬁrmation of the suppression of
c-Myc protein levels (Figs. S1h, l and S6c). While glycolysis was
suppressed (accompanied by a reduction of ATP levels) we
detected a concomitant increase in the oxygen consumption rate,
indicating that activation of oxidative metabolism might partially
counteract for the loss of glycolytic activity (Fig. 2i–k).
Given that genes related to glycolysis were suppressed at the
mRNA level following interference with Aurora kinase A, we
hypothesized that c-Myc may be the transcriptional regulator of
these changes. Although it has been shown earlier that c-Myc can
regulate the expression of HK2 and LDHA, we validated these
ﬁndings in our studied model systems9. To this purpose, SF188
cells were transfected with c-Myc speciﬁc siRNA or non-targeting
siRNA. Protein capillary electrophoresis demonstrated that
silencing of c-Myc suppressed the expression of c-Myc and
related glycolytic targets, SLC2A1, HK2, and LDHA (Fig. S6d).
Next, we linked the effects of Aurora kinase A inhibition on HK2
directly with c-Myc through silencing and over-expression
experiments. As anticipated, when c-Myc is silenced alisertib
did not further reduce the expression levels of HK2 (Fig. S6e).
Next, we intended to functionally connect the effects of Aurora
kinase A on glycolysis via c-Myc. To this end, we performed
silencing experiments followed by a glycolytic stress assay in
GBM22 cells. Genetic interference with c-Myc and Aurora kinase
A led to a suppression of glycolysis and related parameters (Fig.
S6f). Notably, combined silencing of c-Myc and Aurora kinase A
did not result in a further reduction of glycolysis, suggesting that
the effect of Aurora kinase A on glycolysis is largely explained by
c-Myc. Conversely, overexpression of the c-Myc T58A mutant in
SF188 and GBM22 cells attenuate alisertib mediated suppression
of HK2, suggesting that Aurora kinase A regulates the expression
of HK2 via c-Myc (Fig. 2l and Fig. S6g). Next, we assessed
whether over-expression of c-Myc would rescue from alisertibmediated reduction in glycolysis. To this purpose, we transfected
6

c-Myc or T58A mutated c-Myc into SF188 and U87 GBM cells.
Following transfection, cells were exposed to treatment with
alisertib and subjected to extracellular ﬂux analysis (glycolysis
stress assay) (Fig. 2m and Fig. S6h). As anticipated forced
expression of T58A c-Myc rescued from alisertib-mediated
reduction in glycolysis. Next, we assessed whether there is also
reduced binding of c-Myc to the promoter region of HK2. To this
end, we conducted chromatin immunoprecipitation in the vehicle
and acute and chronic treatments with alisertib. As anticipated,
we found that acute and chronic alisertib exposure reduced the
binding of c-Myc to the HK2 promoter in GBM cells, further
conﬁrming the proposed cascade (Fig. 2n and Fig. S6i).
Acute and chronic Aurora kinase A inhibition activates oxidative energy metabolism. While glycolysis was suppressed by
AURKA inhibition, we noted a compensatory increase in the
oxygen consumption rate (Fig. 2j, k). To extend this ﬁnding further, extracellular ﬂux analysis (mitochondrial stress assay) was
performed following acute and chronic inhibition of Aurora kinase
A in several GBM cells. We detected an increase in oxygen consumption rate following acute AURKA inhibition with alisertib
(Fig. 3a and Fig. S7a), while the same conditions yielded a suppression of glycolysis, indicative of a reversal of the “Warburg
effect”. Besides from the acute treatment, it is important to
understand how tumor cells acquire mechanisms to escape from
chemotherapy following constant exposure to a drug and identify
means to prevent this phenomenon from occurring. To generate
drug-resistant cells, they were cultured in the presence of alisertib
for two weeks. These cells acquire partial resistance to alisertib and
display a hyper-oxidative phenotype (Fig. 3b, c, and Fig. S7b, c). To
validate the speciﬁcity of these ﬁndings, we assessed GBM cells
with shRNA or CRISPR-mediated suppression of AURKA. As
anticipated, the increase in oxygen consumption rate was also seen
following genetic interference with AURKA (Fig. 3d and Fig. S7d).
Coupled with this oxidative signature, electron microscopy
revealed an increase in the size of mitochondria with a tubulated
shape following interference with Aurora kinase A signaling
(Fig. 3e). Consistently, acute alisertib treatment showed an increase
in mitochondrial size as assessed by ﬂow cytometric analysis
(Fig. 3f).
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Inhibition of Aurora kinase A and oxidative phosphorylation
is synthetically lethal in GBM model systems and other solid
malignancies. To assess whether OXPHOS inhibition enhances
the efﬁcacy of AURKA inhibition mediated reduction in cellular
viability, we used several OXPHOS complex inhibitors such as
gamitrinib (GTPP, blocks complex II of the respiratory chain),
metformin (blocks complex I of the respiratory chain), and

ARTICLE

oligomycin (inhibits mitochondrial complex V (ATP synthase)).
We launched our studies with gamitrinib to validate that indeed
gamitrinib reversed alisertib mediated increase in oxidative
metabolism. To this end, we utilized extracellular ﬂux analysis
following treatment with vehicle, alisertib, gamtrinib, or the
combination (Fig. 3g). While alisertib increased the oxygen
consumption rate, it was suppressed upon treatment with the

NATURE COMMUNICATIONS | (2021)12:5203 | https://doi.org/10.1038/s41467-021-25501-x | www.nature.com/naturecommunications

7

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25501-x

Fig. 3 AURKA inhibition facilitates oxidative energy metabolism. a GBM22 cells were treated with DMSO or alisertib and analyzed for oxygen
consumption rate (OCR) on a Seahorse XFe24 device. OM: oligomycin, R/A rotenone/antimycin. The graph (right panel) shows the OCR levels (n = 5 in
DMSO, Ali 1 μM, Ali 5 μM; n = 4 in Ali 10 μM independent samples) (Ali 1 μM: *p = 0.0303, Ali 5 μM: **p = 0.0074, Ali 10 μM: *p = 0.0254). For b, c
Seahorse mitochondrial stress assay of parental or chronically alisertib treated GBM22 and SF188 cells. The graph (right panel) shows the mitochondrial
OCR levels (n = 3 in SF188 vs SF188AR, n = 5 in GBM22 vs GBM22AR independent samples) (**p = 0.0014, ***p = 0.0001). d SF188 cells were
transduced with sgRNA against AURKA and were analyzed for the oxygen consumption rate (OCR) on a Seahorse XFe24 device. The graph (right panel)
shows the mitochondrial OCR level (n = 5 independent samples) (**p = 0.0016). e Electron microscopy of parental or chronically alisertib treated U87
cells. Scale bar: 2 µm. Higher magniﬁcation images are shown in the lower panel. Scale bar: 500 nm. The white dotted square shows the enlarged region of
mitochondria in the lower panel. The red arrow highlights the mitochondrial morphology. f GBM22 cells were treated with DMSO or alisertib for 24 h,
labeled with either CellRox or Mitotracker dye, and analyzed by ﬂow cytometry (n = 2 independent samples). g GBM22 cells were treated with 1 µM
alisertib, 2 µM GTPP, or the combination of both for 24 h and analyzed for oxygen consumption rate (OCR) on a Seahorse XFe24 device. The graph (below
panel) shows the mitochondrial OCR level (n = 3 in DMSO and Combination, n = 4 in Ali 1 μM and GTPP 2 μM independent samples) (***p = 0.0001,
****p < 0.0001). For h, i SF188 and GBM22 cells were treated with alisertib, GTPP, or the combination of both for 72 h. Thereafter, cellular viability was
measured, and statistical analysis was performed. Isobolograms are shown. The graphs in (i) show the quantiﬁcation (n = 4 independent samples)
(****p < 0.0001). For j, k SF188 and GBM22 cells were treated with alisertib, oligomycin, or the combination of both for 72 h. Thereafter, cellular viability
was determined and statistical analysis was performed. Isobolograms are shown. The quantiﬁcation is shown in (k) (n = 4 independent samples)
(**p = 0.0015, ****p < 0.0001). Data are shown as mean ± SD in (a−d, g, i, k). Source data are provided as a Source Data ﬁle.

combination of GTPP, in keeping with the notion that oxidative
phosphorylation operates as a pro-survival pathway in the context of AURKA inhibition and that this effect may be reversed by
inhibitors of the electron transport chain (Fig. 3g). Consistently,
we observed a synergistic reduction in proliferation of tumor cells
following the combination treatment with alisertib with either
GTPP, oligomycin, or metformin (Fig. 3h–k and Fig. S7f−h).
Next, we determined whether the combination treatment elicited
in part its effects by enhanced induction of cell death. To this
purpose, we performed annexin V/PI staining and treated several
GBM cells with either vehicle, gamitrinib, alisertib, or the combination of both (Figs. S8a, b). Akin to the viability data, the
combination treatment resulted in enhanced induction of cell
death. In addition, we appreciated a loss of mitochondrial
membrane potential and cleavage of initiator and effector caspases as well as cleavage of PARP which is consistent with
induction of a cell death with apoptotic features (Figs. S8c, d and
S9a). Moreover, we also assessed the protein levels of downstream
regulators of apoptosis, which are orchestrated by anti-apoptotic
Bcl-2 family members. While B-cell lymphoma 2 (Bcl-2), B-cell
lymphoma-extra-large (Bcl-xL), and myeloid cell leukemia 1
(Mcl-1) were reduced following treatment with the combination
treatment, Noxa and ATF4 protein levels were increased (Fig.
S9b), overall in keeping with a pro-apoptotic state.
Aurora kinase A inhibition mediated loss of c-Myc facilitates
an increase in PGC1α to drive oxidative metabolism. Based on a
transcriptome analyses, we found that following alisertib exposure
GBM22 cells activate PPARA pathways (with increases in PGC1α)
and oxidative metabolism accompanied by inhibition of c-MYC
signaling (Fig. 4a). Next, we conﬁrmed that PGC1α is indeed
upregulated as shown in the microarray analysis. To this purpose,
we analyzed mRNA levels of PGC1α by real-time PCR analysis
following acute and chronic treatment with alisertib in several GBM
cell cultures (Fig. 4b, c). In addition, we conﬁrmed that PDK4, a
target of PGC1α, is upregulated as well (Fig. 4d). Next, we assessed
the expression of PGC1α and c-Myc at the protein level. We noted
that both acute and chronic treatments suppressed c-Myc levels,
while enhancing the expression of PGC1α, conﬁrming an inverse
correlation of the two transcription factors (Fig. 4e, f). Similarly,
silencing by shRNA or CRISPR mediated suppression of ARKA also
recapitulate the phenotype elicited by the Aurora kinase A inhibitor
(Fig. 4g, h). Next, we determined whether the inverse relationship of
c-Myc and PGC1α may be appreciated in patients as well. To this
end, we interrogated the TCGA database and found that in GBM
c-Myc levels are elevated as compared to normal brain tissue (Fig.
8

S10a–c). In contrast, PGC1α levels are downregulated in GBM as
compared to normal brain tissue. In addition, we considered the
mRNA expression of c-Myc and PGC1α in individual tumors (GBM
TCGA database, as well as the GBM PDX Mayo Clinic database)
and found that high levels of c-Myc were correlated with low levels
of PGC1A mRNA in a statistical signiﬁcant manner (Fig. S10b, c).
To elucidate a better understanding, how the transcriptional increase
of PGC1α is facilitated by Aurora kinase A inhibition, we performed
CHIP-seq and ATAC-seq19 analysis and checked the PGC1α promoter and enhancer region for potential transcription factor binding
sites. We noted that the chromatin accessibility as shown by
H3K27ac CHIP-seq and ATAC-seq was increased at a potential
c-Myc binding region (Fig. 4i). To conﬁrm this observation, we
performed chromatin immunoprecipitation of c-Myc and ampliﬁed
the PGC1α promoter region in GBM cells either treated with vehicle
or with alisertib. While we found strong binding of c-Myc to the
PGC1α promoter in vehicle-treated cells, reduced binding was
detected following exposure to alisertib (Fig. 4i–k and Fig. S11a).
Notably, we found an enhanced acetylation of the same region
following alisertib inhibitor treatment, suggesting that c-Myc may
act as a suppressor of PGC1α (Fig. 4i–k and Fig. S11a). To further
validate this hypothesis, we performed epistasis experiments involving, over-expression and silencing of c-Myc in the context of
AURKA inhibition. To this end, we transfected c-Myc and T58A
mutant c-Myc in GBM22. Following transfection, GBM22 cells were
treated with increasing concentrations of alisertib and assessed for
mRNA levels of PGC1α. We noted that forced expression of the
T58A c-Myc mutant attenuated alisertib-mediated increase in
PGC1α mRNA levels (Fig. 4l). These results were conﬁrmed on the
protein level as well (Fig. 4m). Next, we wondered whether c-Myc
over-expression could reverse the increase of PGC1α in alisertibresistant GBM22 cells. Indeed, we observed that adenoviralmediated over-expression of c-Myc suppressed PGC1α levels (Fig.
S11b). Consistently, when we silenced c-Myc there is no further
increase of PGC1α level upon alisertib treatment (Fig. 4n and Fig.
S11c, d). These ﬁndings support the notion that c-Myc is involved in
the regulation of PGC1α and that c-Myc potentially acts as a suppressor of PGC1α. Next, we determined the functional role of
PGC1α in the context of Aurora kinase A inhibition. To this end, we
silenced PGC1α in GBM22 and SF188 cells and treated them with
increasing concentrations of alisertib. We found that silencing of
PGC1α enhanced the efﬁcacy of alisertib to reduce the cellular
viability of the indicated GBM cells (Fig. 4o), suggesting that PGC1α
acted as a pro-survival factor in the context of Aurora kinase A
inhibition. We hypothesized that PGC1α is at least partially
responsible for Aurora kinase A inhibition mediated increase in
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oxygen consumption rate (Fig. 4p). As above, parental or alisertib
treated SF188 cells were transfected with non-targeting or PGC1α
speciﬁc siRNA. Subsequently, cells were subjected to extracellular
ﬂux analysis on the seahorse analyzer. While PGC1α had little effect
on the oxygen consumption rate in parental SF188 GBM cells, there
was a signiﬁcant reduction in oxidative metabolism in alisertib
treated cells, indicating that PGC1α does not appear to play a major

ARTICLE

role in parental cells, but impacts oxygen consumption in GBM cells
exposed to alisertib (Fig. 4p). All in all, these ﬁndings support the
notion that alisertib-driven activation of oxidative phosphorylation is
pro-survival, which in part is mediated by PGC1α. We also validated
whether c-Myc silencing would elevate oxygen consumption rate
given its suppressive effects on PGC1α and whether loss of c-Myc is
responsible in part for the upregulation of the oxygen consumption
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Fig. 4 AURKA inhibition drives PPARA signaling leading to an increase of PGC1α in a partial c-Myc dependent manner. a Parental or chronically
alisertib treated GBM22 cells were subjected to transcriptomic analysis and followed by GSEA. Shown are the enrichment plots of Hallmark_Myc_Target
and Biocarta_PPARA_Pathway. NES: normalized enrichment score. FDR: false discovery rate. b Real-time PCR analysis of PGC1α mRNA levels in SF188,
GBM22, and U87 treated with alisertib or DMSO (n = 8 in SF188 and U87, n = 4 in GBM22 independent samples) (*p = 0.0116, ****p < 0.0001). c Realtime PCR analysis of PGC1α mRNA levels in parental or alisertib chronically exposed SF188, GBM22, and U87 cells (n = 8 independent samples)
(****p < 0.0001). d Real-time PCR analysis of PDK4 mRNA levels of parental or alisertib chronically exposed SF188, GBM22, and U87 cells (n = 3 in SF188
and SF188AR, n = 4 in GBM22 and GBM22AR, n = 3 in U87 and n = 4 in U87AR independent samples) (****p < 0.0001). FC: fold change. e Protein
capillary electrophoresis for the indicated proteins of GBM22 and SF188 cells treated with alisertib for 24 h. Vinculin is used as a loading control. f Protein
capillary electrophoresis for the indicated proteins of parental or chronically alisertib treated GBM22 or SF188 cells. g GBM22, SF188, and U87 cells were
transduced with scrambled or shARKA and the whole-cell lysates were subjected to protein capillary electrophoresis with the indicated antibodies. h SF188
cells were transduced with scramble or sgAURKA and the whole-cell lysates were subjected for protein capillary electrophoresis with the indicated
antibodies. i ChIP-sequencing (H3K27ac) and ATAC-sequencing were performed in parental or chronically alisertib treated GBM22 cells. Shown are the
respective tracks around the PPARGC1A locus. j Parental or chronically alisertib treated GBM22 and SF188 cells were subjected to CHIP with an IgG as a
negative control or a c-Myc speciﬁc antibody. The PGC1α region was ampliﬁed by PCR (n = 3 independent samples) (****p < 0.0001). k Parental or
chronically alisertib treated GBM22 and SF188 cells were subjected to CHIP with an IgG as a negative control or a H3K27ac speciﬁc antibody. The PGC1α
region was ampliﬁed (n = 3 independent samples) (****p < 0.0001). l Real-time PCR analysis of PGC1α mRNA levels of GBM22 cells transfected with cMyc-WT and c-Myc mutant (T58A) followed by treatment with increasing concentrations of alisertib (n = 4 independent samples). m GBM22 and SF188
cells were transfected with c-Myc-WT and c-Myc mutant (T58A), treated with alisertib for 24 h, and the whole-cell lysates were subjected to protein
capillary electrophoresis with the indicated antibodies. n GBM22 cells were transfected with non-targeting or two speciﬁc siRNAs targeting Myc, treated
with 10 µM alisertib for 24 h, and the whole-cell lysates were subjected to protein capillary electrophoresis. o GBM22 and SF188 cells were transfected with
non-targeting or speciﬁc PGC1α siRNA, treated with increasing concentration of alisertib for 72 h, and cellular viability was analyzed (n = 4 independent
samples). IC50 in µM range in GBM22 and in nM range in SF188. p Parental or chronically alisertib treated SF188 cells were transfected with non-targeting
siRNA or PGC1α speciﬁc siRNA and analyzed for oxygen consumption rate (OCR) on a Seahorse XFe24 device. The graph (right panel) shows the OCR
level (n = 3 independent samples) (***p = 0.0007, ****p < 0.0001). Statistical signiﬁcance was assessed by a two-tailed student’s t-test in (b−d, j, k) or
ANOVA with Dunnett’s multiple comparison test in p. Data are shown as mean ± SD in b−d, j−l, o, p). Source data are provided as a Source Data ﬁle.

rate following silencing of AURKA. To this end, we transfected
SF188 GBM cells with siRNA against MYC, AURKA, or the combination (Fig. S11f). Thereafter, we analyzed both oxygen consumption rate and extracellular acidiﬁcation rate to determine the
ratio of the two metabolic indicators. Consistently, we found an
elevation of the OCR/ECAR ratio following transfection with all
siRNAs, indicating that reduced c-Myc or AURKA levels indeed
shift the glycolytic to an oxidative phenotype in GBM cells. The
combined silencing did not further enhance this effect, in keeping
with the hypothesis that the enhanced oxidative phenotype elicited
by silencing AURKA is likely to be a mediated by AURKA driven
loss of c-Myc. Given the regulation of both PGC1α and c-Myc on
mitochondrial energy metabolism, it was evident to analyze the size
of mitochondria following c-Myc and PGC1α modulation in the
context of Aurora kinase A inhibition. Silencing of PGC1α suppressed alisertib mediated increase in mitochondrial size as indicated
by mito-tracker staining (Fig. S11g). Consistently, adenoviralmediated over-expression of c-Myc mirrored the ﬁndings obtained
following genetic interference with PGC1α expression (Fig. S11h),
suggesting that c-Myc and PGC1α are implicated in ﬁssion and
fusion of mitochondria following AURKA inhibition.
Inhibition of Aurora kinase A reduces both glucose and glutamine oxidation, but leads to enhanced oxidation of palmitic
acid. Localized in the matrix of mitochondria, the citric acid cycle
(TCA cycle) is a central metabolic process that has both catabolic
and anabolic functions (Fig. 5a). Glucose carbons are metabolized
to yield pyruvic acid which either will be converted to oxaloacetate (pyruvate carboxylase) or acetyl-CoA (pyruvate dehydrogenase), while glutamine enters the TCA-cycle via glutamate.
Long-chain fatty acids are oxidized in beta-oxidation to yield the
ﬁnal product acetyl-CoA, which condenses with oxaloacetate to
give rise to citric acid (Fig. 5a). We wondered how Aurora kinase
A inhibition affects metabolic fuel utilization since such information might reveal additional metabolic liabilities. To address
this question, we determined the fate of uniformly labeled U-13Cglucose, U-13C-glutamine, and U-13C-palmitic acid carbons following treatment with alisertib in both PDX and established
10

GBM cells (Fig. 5b–e and Fig. S12a−d). As anticipated and
consistent with the extracellular ﬂux analysis, we found that both
the m + 3 isotopologue of pyruvate and lactate showed reduced
labeling from glucose carbons (Fig. 5c and Fig. S12b). Consistently, the m + 0 isotopologues of pyruvate and lactate were
increased, consistent with an overall reduction of labeling of these
two metabolites, in keeping with a suppression of the Warburg
effect (Fig. 5c and Fig. S12b). While the labeling of the m + 2
citric acid isotopologue was reduced in samples cultured with U13C-glucose we detected an increase in labeling from U13C-palmitic acid. To maintain fatty acid oxidation, anaplerosis is
supportive, which is facilitated through pyruvate carboxylase
mediated generation of oxaloacetate (from glucose carbons), for
which the presence of the m + 3 or m + 5 isotopologue of citric
acid serves as a surrogate. While we noted an increase for both
isotopologues in U87 GBM cells, the GBM22 PDX cells revealed
only a substantial increase in the m + 5 citric acid isotopologue.
These ﬁndings suggest that enhanced fatty acid oxidation is in
part supported through anaplerosis following alisertib inhibition
treatment. Another interesting observation is that in U87 GBM
cells we found evidence of reductive carboxylation by virtue of an
increase of the m + 5 citric acid isotopologue (from glutamine
carbons), but this effect was not seen in the GBM22 cells (Fig. 5d
and Fig. S12c), indicating that cell-type-speciﬁc metabolic fuel
utilizations are likely involved. While glutamine fuel utilization
was reduced, we found enhanced labeling of amino acids from
palmitic acid-derived carbons, in keeping with a key role for fatty
acids in Aurora kinase A inhibition mediated metabolic reprogramming in model systems of GBM (Fig. 5e and Fig. S12d).
Acute and chronic inhibition of Aurora kinase A signaling
gives rise to metabolic reliance on fatty acid oxidation. Our
integrated transcriptome, CHIP sequencing, and non-polar
metabolites analyses in parental and alisertib treated GBM22
cells demonstrated a profound transcriptional, epigenetic, and
metabolic reprogramming of fatty acid oxidation, i.e., upregulation of very long-chain speciﬁc acyl-CoA dehydrogenase
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Fig. 5 AURKA inhibition impacts central carbon metabolism resulting in enhanced labeling of TCA cycle metabolites by long-chain fatty acids. a
Summary of key reactions related to the tracer experiment. Blue circles indicate 13C carbons from glutamine, brown circles indicate 13C carbons from
palmitic acid, whereas red circles highlight 13C carbons from glucose. Black circles are used to display 12C carbons. b, c Parental or chronically alisertib
treated GBM22 cells were cultured in DMEM media containing 25 mM U-13C glucose, 4 mM glutamine and 10% dialyzed FBS and were subjected to LC/
MS analysis (n = 3 independent samples) (pyruvic acid: *p = 0.0492, lactic acid: *p = 0.019). d Parental or chronically alisertib treated GBM22 cells were
cultured in DMEM media containing 25 mM glucose, 4 mM U-13C glutamine and 10% dialyzed FBS and were subjected to LC/MS analysis (n = 3
independent samples). e Parental or chronically alisertib treated GBM22 cells were cultured in DMEM media containing 5 mM glucose, 1 mM glutamine,
100 µM U-13C palmitic acid, and 10% dialyzed FBS and were subjected to LC/MS analysis. Shown are relative percentages of the isotopologues for each
metabolite (n = 3 independent samples). Data are shown as mean ± SD in (b−e). Source data are provided as a Source Data ﬁle.

(ACADVL), short/branched-chain speciﬁc acyl-CoA dehydrogenase (ACADSB), electron transfer ﬂavoprotein dehydrogenase (ETFDH)) and fatty acids transporters (CPT1C and
CD36) (Fig. 6a–f and Fig. S13a−c). The transcriptional ﬁndings
were conﬁrmed by real-time PCR analysis (Fig. 6c and Fig. S13d).
Chip-seq. (H3K27ac) indicated a substantial epigenetic reprogramming with an increase in total peaks following alisertib
exposure, which was reﬂected by enhanced peak formation in

areas close to genes involved in FAO (Fig. S13c). With regards to
the non-polar metabolite analyses, we noted a substantial increase
of acyl-carnitines and an elevation of lysophosphatidyl derivatives, strongly suggestive of an increase in fatty acid oxidation in
alisertib exposed tumor cells and in keeping with our metabolic
fuel dependency analysis (Fig. 6d–f). We also assessed whether
c-Myc is implicated in the increase of enzymes and transporters
related to fatty acid oxidation. To this end, parental and alisertib
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treated GBM22 cells were transduced with a c-Myc adenovirus,
and following transduction the mRNA levels of enzymes related
to fatty acid oxidation were analyzed. We found that indeed
certain enzymes were suppressed following c-Myc over-expression, suggesting that loss of c-Myc mediated by Aurora kinase A
inhibition is partially implicated in the engagement of fatty acid
oxidation (Fig. S13e). These observations prompted us to test the
hypothesis that alisertib along with the clinical validated FAO
inhibitor, etomoxir, which binds and blocks the mitochondrial
12

fatty acid transporter CPT1A, would reduce the cellular viability
of GBM cells in a more than additive manner. Indeed, we found
that the combination treatment reduced the growth of GBM cells
in a synergistic manner (Fig. 6g, h, and Fig. S13f−i). Notably,
astrocytes were less responsive to the combination treatment,
suggesting a favorable toxicity proﬁle (Fig. S13j). We next asked
whether the combination treatment of alisertib and etomoxir
resulted in enhanced cell death as well (Fig. S14a−f). Flow
cytometry data revealed enhanced apoptosis and dissipation of
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Fig. 6 Dual inhibition of FAO and AURKA elicits a synergistic reduction in cellular viability of GBM cells. For a, b parental or chronically alisertib treated
GBM22 cells were subjected to transcriptomic analysis and followed by GSEA. Shown are a graphical plot of NES vs FDR-q value of microarray data in (a) and an
enrichment plot of Go_Regulation_of_Fatty_Acid_Oxidation in (b). NES: normalized enrichment score. FDR: false discovery rate. c Real-time PCR analysis of genes
related to fatty acid oxidation (mRNA levels) of parental or chronically alisertib treated GBM22 cells (n = 8 in GBM22 and n = 4 in GBM22AR independent
samples). FC: fold change. d Non-polar metabolite analysis of parental or chronically alisertib treated GBM22 cells. A heatmap of parental or chronically alisertib
treated GBM22 cells is shown. AcCa: acyl carnitine; Cer: ceramides; CerG1-3: neutral glycosphingolipids. CerP: phosphosphingolipids; ChE: cholesterol Ester; DG:
diglyceride; LPC: lysophosphatidylcholine; LPE lysophosphatidylethanolamine; LPI: lysophosphatidylinositol; LPS: lysophosphatidylserine; PC: phosphatidylcholine;
PE: phosphatidylethanolamine; PG: phosphatidylglycerol; PI: phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin; So: sphingosine; TG: triglyceride. For
e, f acyl-carnitine and lysophosphatidyl levels in the non-polar metabolite analysis of parental or chronically alisertib treated GBM22 cells (n = 5 independent
samples). For g, h Parental or chronically alisertib treated GBM22 and SF188 cells were treated with alisertib, etomoxir, or the combination of both for 72 h, and
cellular viability was analyzed. Isobolograms are shown in (g) and quantiﬁcation of cell viability is shown in (h) (n = 4 independent samples) (**p = 0.0047,
***p = 0.0002, ****p < 0.0001). i Parental or chronically alisertib treated GBM22 cells were treated with alisertib, etomoxir, or the combination of both for 24 h
and analyzed for oxygen consumption rate (OCR) on a Seahorse XFe24 device. The graph (right panel) shows the OCR level (n = 5 independent samples)
(*p = 0.0195, ****p < 0.0001). j SF188 cells were transfected with non-targeting siNT or siAURKA (single or pool), treated with etomoxir for 72 h, and cellular
viability was analyzed (n = 4 independent samples) (siAURKA-2: *p = 0.0181, siAURKA-4: *p = 0.1015). For k, l SF188 cells were transfected with non-targeting
siNT or CPT1A speciﬁc siRNA (siCPT1A), treated with alisertib for 72 h, and cellular viability was analyzed (n = 7 in siNT + DMSO, n = 8 in siCPT1A + DMSO,
n = 4 in siNT + Ali 20 nM and siCPT1A + Ali 20 nM independent samples) (*p = 0.0495, ***p = 0.0009). Protein capillary electrophoresis conﬁrms the
silencing of CPT1A is shown in l. Vinculin is used as a loading control. Statistical signiﬁcance was assessed by a two-tailed student’s t-test in (j, k) or ANOVA with
Dunnett’s multiple comparison test in (h, i). Data are shown as mean ± SD in (c, e, h−k). Source data are provided as a Source Data ﬁle.

mitochondrial membrane potential in the combination treatment
of alisertib and etomoxir as compared to single treatments and
vehicle (Fig. S14a−f). Notably, minimal cell death induction was
detected by the combination treatment in astrocytes, favoring a
tumor-speciﬁc effect (Fig. S14c, d). Next, we tested whether the
increase in OCR related to Aurora kinase A inhibition is attenuated in the context of the combination treatment with etomoxir. We found that the alisertib-mediated increase in OCR was
attenuated in the presence of etomoxir (Fig. 6i). To conﬁrm the
speciﬁcity of the ﬁndings obtained from the drug compounds, we
took a two-pronged strategy by silencing their presumed molecular targets, AURKA (alisertib) and CPT1A (etomoxir). Genetic
inhibition of AURKA (siRNA) enhanced the efﬁcacy of etomoxir
to reduce the cellular viability of GBM cells (Fig. 6j). Conversely,
silencing of CPT1A sensitized GBM cells for alisertib-mediated
reduction of cellular viability (Fig. 6k, l).
Dual inhibition of Aurora kinase A along with oxidative
energy metabolism extends overall survival in PDX models of
glioblastoma in mice. Considering the in vitro ﬁndings related to
the various drug combinations, involving Aurora kinase A inhibition and targeting of tumor metabolism we assessed whether
these observations bear translational relevance. To this purpose,
we harnessed PDX models since they are currently the premier
model system to study drug effects in a preclinical setting in vivo.
The appeal of PDX tumor model systems is based on the fundamental principle that they keep most features of the primary
tumors and therefore likely provide the closest resemblance to a
patient scenario. First, we initiated the in vivo studies with two
subcutaneous GBM patient-derived xenograft models, GBM12
and GBM43. Following the establishment of tumors, mice were
randomly divided into four groups: vehicle, alisertib (30 mg/kg),
etomoxir (20 mg/kg), and the combination of both. We detected a
stronger suppression in tumor growth in animals that received
both alisertib and etomoxir treatment as compared to the single
treatments in both the GBM12 and GBM43 models (Fig. 7a–d).
In addition, we determined whether a combined inhibition of
mitochondrial Hsp90 and Aurora kinase A leads to enhanced
growth inhibition in PDX models of GBM. To this end, we tested
the combination treatment of gamitrinib and alisertib in the
GBM12 PDX model. Akin to the ﬁndings related to the FAO
inhibitor, the combination treatment of alisertib and gamitrinib
reduced tumor growth more potently than single treatment with

alisertib (Fig. S15a, b). Having observed substantial tumorsuppressive effects in model systems of malignant glioma, we
sought to determine whether these combination treatments are
similarly efﬁcacious in other solid malignant tumors as well. To
this end, we chose colonic adenocarcinoma as a common solid
malignancy and utilized the HCT116 xenograft model to assess
the various treatments in vivo. Following the establishment of
tumors, six groups were formed, consisting of vehicle, alisertib
(30 mg/kg), etomoxir (20 mg/kg), gamitrinib (5 mg/kg), alisertib + gamitrinib, and alisertib + etomoxir. Similar to the GBM
models the combination treatments reduced the growth of the
tumor cells more potently than the single treatments, suggesting
that the approach to combine metabolic inhibitors along with
Aurora kinase A blockers are likely applicable to a broader range
of solid malignancies (Fig. S15c, d).
Next, we assessed whether the metabolic in vitro ﬁndings are
observed in the animals as well. To this purpose, we injected
tumor (GBM12 PDX) bearing animals from both the vehicle and
alisertib treated group with U-13C-palmitic acid and submitted
the tumors for LC/MS analysis. We found that tumors treated
with alisertib displayed enhanced labeling of both TCA-cycle
metabolites, as well as amino acids from palmitic acid carbons, in
keeping with the notion that Aurora kinase A inhibition facilitates
fatty acid oxidation in vivo as well (Fig. 7e). In addition, we
assessed whether in vivo PGC1α is upregulated following
treatment with alisertib. We found that PGC1α was increased
and more abundantly present in tumors treated with alisertib
(Fig. 7f), indicating that likely PGC1α is implicated in the
metabolic reprogramming in vivo as well.
To gain more insight about the impact of the drug
treatments on the cellular density, proliferation, and cell
death (necrosis and apoptosis), representative tumors were
parafﬁn-embedded and stained with hematoxylin and eosin
(H&E). While vehicle, etomoxir, and alisertib-treated tumors
displayed a dense cellular architecture with brisk mitotic
activity, the combination treatment showed lower cellular
density with a reduction of mitosis and areas of cell death (Fig.
S15e). To conﬁrm cell death induction by the combination
treatment, TUNEL staining was performed (Fig. S15f−h). We
detected more TUNEL positive cells in tumors exposed to the
combination treatment as compared to vehicle or single-drug
treatments. Consistently, the proliferation index (Ki67) was
noted lesser in the combination treatment (Fig. S15f−h).
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These ﬁndings are in keeping with the reduced size of the
tumors in the combination treatment. Similar ﬁndings were
made in tumors that were treated with vehicle, gamitrinib,
alisertib, or the combination of both (Fig. S15i−l). The
integrity of solid organs such as heart or kidney was assessed
and we did not observe induction of detectable toxicity in the
combination treatment (Fig. S16a).
14

Given the signiﬁcant promise in the heterotopic GBM
xenograft studies, we extended our study to orthotopic PDX
models of glioblastoma given that these model systems, though
with some limitations, are currently considered to be in closest
resemblance to the patient scenario. To this purpose, we utilized
the GBM12 and GBM22 PDX orthotopic xenograft models,
respectively. After the establishment of tumors, four groups of
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Fig. 7 Dual inhibition of FAO and AURKA extends animal survival in orthotopic patient-derived xenograft models of human GBM. For a, b GBM12 cells
were implanted into the subcutis of immunocompromised Nu/Nu mice. After the tumors were established, the mice were randomized to four treatment
groups: vehicle, alisertib (30 mg/kg), etomoxir (20 mg/kg), and the combination treatment. The tumor volume over time is shown in (a) and the tumor
volume on the last day of the experiment is shown in (b) (n = 8 in alisertib and etomoxir, n = 9 in vehicle and combination independent tumors)
(*p = 0.0438, **p = 0.0085, ***p = 0.0003). For c, d GBM43 cells were implanted into the subcutis of immunocompromised Nu/Nu mice. After the
tumors were established, the mice were randomized to four treatment groups: vehicle, alisertib (30 mg/kg), etomoxir (20 mg/kg), and combination
treatment of both. The tumor volume over time is shown in (c) and the tumor volume on the last day of the experiment is shown in (d) (n = 9 in vehicle
and etomoxir, n = 12 in alisertib and combination independent tumors) (Ali vs Combination: *p = 0.0462, etomoxir vs combination: *p = 0.0162). e GBM12
cells were implanted and treated with alisertib, etomoxir, or the combination of both as described in (a). On the last day of the experiment, mice were
injected with 100 µM U-13C-palmitic acid for 4 h and tumors were subjected to LC/MS. The graph shows the U-13C-palmitic acid labeling of the TCA cycle.
FC: fold change. f Tumors from the experiment in (a) were ﬁxed and stained with PGC1α. Scale bar: 50 µM. For g, h GBM12 and GBM22 cells were
implanted in the right striatum of nude mice. Four groups were randomly assigned: vehicle, alisertib, etomoxir, and combination of both, seven days after
the implantation. Mice were treated three times per week and animal survival is provided (Kaplan−Meier-curve): vehicle: GBM12: 20d, GBM22: 20d;
alisertib: GBM12: 28d, GBM22: 22d; etomoxir: GBM12: 25.5d, GBM22: 19.5d; combination: GBM12: 37.5d, GBM22: 26d. The log-rank test was used to
assess statistical signiﬁcance (n = 5 in vehicle and alisertib, n = 4 in etomoxir, n = 6 in combination). For (i−k) The brain tumors from the experiment in
(h) were ﬁxed and stained with H&E, TUNEL, or Ki67. Scale bar: 50 µm. l Quantiﬁcation of TUNEL and Ki67 positive cells in (j, k), respectively (n = 5 in
vehicle, etomoxir, combination, n = 6 in alisertib independent high-power ﬁeld microscopy) (***p = 0.0001, ****p < 0.0001). Statistical signiﬁcance was
assessed by a two-tailed student’s t-test in e or ANOVA with Dunnett’s multiple comparison test in (b, d, l). Data are shown as mean ± SEM in (a, c) and
as mean ± SD in (b, d, e, l). Source data are provided as a Source Data ﬁle.

animals were formed: vehicle, alisertib, etomoxir, and combination of both (Fig. 7g, h). In both models, we found that the
combination treatment extended animal survival signiﬁcantly
longer than compared to a single treatment with alisertib (Fig. 7g,
h), suggesting potential clinical efﬁcacy. Consistently, orthotopic
tumors that received treatment with the combination treatment
were smaller than vehicle or single-agent treated tumors as
indicated by histopathological evaluation (Fig. 7i–l and Fig. S16b).
In addition, they displayed an increase in TUNEL positive GBM
cells and a reduced amount of Ki67 positive GBM cells as
compared to single treatments (Fig. 7l). Collectively, our data
provide a foundation for further evaluation and potential clinical
consideration of drug combination therapies, involving AURKA
and FAO/OXPHOS inhibitors.
Discussion
The exploration of tumor cell metabolism has recently gained
more traction in cancer research1,5,8,18,20–35. Through the recent
advancement in high throughput, genetic techniques and medicinal chemistry direct targeting of key enzymes of metabolism
have become more achievable and tractable than in the past.
However, brain tumor metabolism has been relatively understudied and it appears likely that additional knowledge in this
ﬁeld will foster treatment approaches for these devastating diseases. The general dogma of cancer cell metabolism is centered on
aerobic glycolysis (Warburg-effect), but how this effect in detail is
regulated remains enigmatic. The resolution of this complex
interplay will likely yield substantial insights into the pathophysiology of solid and non-solid malignancies and the design of
more efﬁcient therapies. In this study, we made the unique
observation that Aurora kinase A inhibition is synthetically lethal
with the interference of the respiratory transport chain in solid
malignancies. While Aurora kinase A is considered to modulate
cell proliferation through modulation of mitosis, we here made
the unexpected, but the important discovery that Aurora kinase A
inhibition stalled the proliferation of GBM cells in a manner that
was highly dependent on glycolysis. Whereas Aurora kinase A
inhibition resulted in suppression of glycolysis, it concomitantly
activated oxidative metabolism, suggesting that metabolic reprogramming might represent an escape mechanism of GBM cells
from therapy. When cells were cultured in galactose, they were
signiﬁcantly more resistant towards reduction of cellular viability
mediated by Aurora kinase A inhibitors, suggesting that tumor
cells with an oxidative energy metabolism will display resistance

towards AURKA inhibitor treatment. Consistently, alisertibresistant GBM cells displayed a hyper oxidative phenotype.
These ﬁndings are signiﬁcant because it is known that tumor cells
may display a range of dependency on either glycolysis or oxidative phosphorylation, which nowadays may be assessed rapidly.
Therefore, the grouping of tumors according to their metabolism
might predict response and resistance to therapies, involving
AURKA inhibitors. These results are in contrast with other
inhibitors that target oxidative energy metabolism, e.g., LXR
agonists and CLPP protease activators36–38. In these instances,
galactose exposure renders tumor cells more susceptible to such
compounds, reinforcing the role of this approach to distinguish
between glycolytic or oxidative energy metabolism dependency.
Given that there is a broad array of compounds available that
block oxidative metabolism, we utilized classical inhibitors of
oxidative metabolism to demonstrate that dual inhibition of the
electron transport chain and Aurora kinase A inhibition is synthetically lethal in a model system of GBM and in a model system
of colorectal carcinoma. To the best of our knowledge, these
ﬁndings have not been reported elsewhere before even not in
other tumor entities. Given that we have validated our results
beyond GBM models (i.e., in a colonic carcinoma xenograft)
there is a reasonable likelihood that other solid tumors may
respond in a similar fashion.
Aerobic glycolysis is controlled by c-Myc and interference with
this transcription factor has been shown to suppress glycolysis
and in turn tumor growth in a variety of different tumor model
system even in contexts where MYC is not ampliﬁed9. Our
proteomic analysis suggested that Aurora kinase A inhibitors
blocked c-Myc levels. Silencing and over-expression of c-Myc
implied a causal role for c-Myc. Ablating c-Myc from GBM cells
resulted in enhanced resistance towards Aurora kinase A inhibition mediated reduction in cellular viability. Consistently,
modest over-expression of c-Myc rescued partially rescued from
alisertib mediated loss in cellular viability, consistent with earlier
ﬁndings in the context of neuroblastoma (MYCN/AURKA)39.
Co-immunoprecipitation studies further suggested a direct
interaction between Aurora kinase A and c-Myc and that Aurora
kinase A counteracted c-Myc degradation by the proteasome. Our
results provide evidence of this interaction in these settings.
Moreover, both the fact that AURKA signaling regulates tumor
cell metabolism through c-Myc is important and that the
response to AURKA inhibitors relies on tumor metabolism
(balance between glycolysis and oxidative phosphorylation) via

NATURE COMMUNICATIONS | (2021)12:5203 | https://doi.org/10.1038/s41467-021-25501-x | www.nature.com/naturecommunications

15

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25501-x

c-Myc is relevant even beyond the current studies given that any
treatment modality, involving AURKA inhibitors, will be most
likely inﬂuenced by the metabolic status of the tumor. Prior
results in other tumor entities pointed towards a role of Aurora
kinase A in regulating glycolysis and oxidative energy metabolism, but our results are unique due to the identiﬁed signaling
pathway and its potential translational implications40–42.
While glycolysis and c-Myc levels declined following Aurora
kinase A pathway perturbation, we noted an increase of the
oxygen consumption rate accompanied by an elevation of
PGC1α, suggesting both an inverse correlation between glycolysis
and oxidative metabolism, as well as between c-Myc and PGC1α.
Following ATAC-seq. analysis of the PGC1α promoter region we
noted enhanced accessibility at a MYC binding region. Our
experiments strongly suggest that c-MYC acted as a repressor of
PGC1α expression in a PDX model system of GBM. Importantly,
PGC1α caused resistance to Aurora kinase A inhibition mediated
reduction in cellular viability, which up to date has not been
described before. Given the existence of PGC1α inhibitors and
considering our ﬁndings it may also be tempting to speculate
whether such drugs could synergize with AURKA inhibitors to
reduce the proliferation of tumor cells.
The following interference with AURKA signaling our comprehensive metabolite analysis revealed strong evidence of reliance of GBM cells on fatty acid oxidation, shifting away from
their glycolytic phenotype. Indeed, extracellular ﬂux and carbon
tracing analyses conﬁrmed this notion, and inhibition of FAO or
the electron transport chain along with Aurora kinase A blockage
is synthetically lethal in GBM model systems and other recalcitrant solid malignancies, e.g., colon carcinoma. Utilizing the
current gold standard for preclinical drug assessment for GBM,
we were able to demonstrate that the combination treatment of
alisertib with inhibitors of FAO extended animal survival. All in
all, our ﬁndings reinforce the concept that targeting drug-induced
reprogrammed GBM metabolism is feasible, which may have
future therapeutic implications.
Methods
Cell cultures and growth conditions. All cell lines were incubated at 37 °C and
were maintained in an atmosphere containing 5% CO2. GBM22, GBM12, and
GBM43 cells were obtained from Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN)
between 2014 and 2020. GBM12 is a PDX line, which is derived from a male
patient (glioblastoma, IDH-wildtype, mesenchymal molecular subtype, EGFR
ampliﬁed, PTEN wt, TP53 mutated (splice mutation), MYC non-ampliﬁed).
GBM22 is a PDX line, which is derived from a male patient (Gliosarcoma, IDHwildtype, classical molecular subtype, IDH1 wt, EGFR gain, PTEN wt, TP53
mutated, MYC ampliﬁed). GBM43 is a PDX line, which is derived from a male
patient (Glioblastoma, IDH-wildtype, classical molecular subtype, IDH wt, EGFR
gain, PTEN wildtype, TP53 mutated, MYC non-ampliﬁed). U87 and HCT116 cell
lines were obtained from the American Type Culture Collection (Manassas, VA).
Cells were cultured in DMEM (Fisher Scientiﬁc, MT10013CV), 10% FBS (Gemini)
and 100 μg/ml of Primocin (Invivogen, ant-pm-1). SF188 cells were obtained from
UCSF (CA) and were cultured in DMEM, 10% FBS, 1% Glutamax (Thermo Fisher,
35050061), and 100 μg/ml of primocin. SF188 is a pediatric glioblastoma cell line
derived from 8-year old male (TP53 mut, PTEN wt, MYC-ampliﬁed). Astrocyte
cells were obtained from ScienceCell Research Laboratories (Carlsbad, CA) and
were cultured in DMEM, 10% FBS, primocin, and N2 supplement (Thermo Fisher,
17502048). Alisertib resistant cells were established by continuous exposure to
alisertib for 10 days. For the treatment experiment, cells were cultured in DMEM
containing 1.5% FBS. The respective cell line depository authenticated the cells.
Reagents. Alisertib (MLN8237), etomoxir (S8244), metformin (S1950), and oligomycin (S1478) were purchased from Selleckchem (Houston, TX). Gamitrinib
(GTPP) was provided by Dr. Altieri (Wistar Institute, Philadelphia, PA). Galactose
was purchased from Sigma (G0750, Burlington, MA). A 10 mM working solution
in dimethylsulfoxide (DMSO) was prepared for all reagents prior to storage at
−20 °C. Final concentrations of DMSO were below 0.1% (v/v). MG-132 (4747915MG) and Cycloheximide (239764-100MG) were purchased from Sigma.
Plasmid constructs. AURKA-Untagged (EX-Q0008-M02) and HA-AURKA (EXQ0008-M06) were purchased from GeneCopoeia (Rockville, MD). pCDH-MSCV16

T2A-puro, pCDH-MSCV-T2A-puro-Flag-Myc WT, and pCDH-MSCV-T2Apuro-Flag-Myc T58A were generously given by Dr. Shideng Bao (Cleveland Clinic,
Cleveland, OH), pcDNA6-N-3XFLAG-GSK3β (Cat #123592), FLAG-HApcDNA3.1 (Cat# 52535), and pCDNA3-HA-HA-humanCMYC (Cat #74164) were
purchased from Addgene (Watertown, Massachusetts).
Cell viability assays. Cells were seeded in a 96-well plate with density 3 × 103 cells
per well and allowed to attach overnight. To examine cellular proliferation,
CellTiter-Glo® assays were performed according to the manufacturer’s instructions
(Promega, G7571) and the signal was read by using the SpectraMax i3x (Molecular
Device, San Jose, CA). To determine drug synergism the median effect equation
(Chou—Talalay) was employed (isobolograms and the combination index (CI)).
Flow cytometry. Cells were seeded in a 12 well plate with density 3 × 104 cells per
well and allowed to attach overnight. To detect the apoptosis and necrosis, cells
were incubated with FITC Annexin V/ propidium iodide according to the manufacturer’s instructions (BD Biosciences, 556420). To detect intrinsic apoptosis
staining and loss of mitochondrial membrane potential, TMRE (tetramethylrhodamine ethyl ester perchlorate) staining was performed according to the
manufacturer’s instructions (CST, 13296S). Signal was detected on a LSRII ﬂow
cytometry (Becton–Dickinson, New Jersey) and the data were analyzed with FlowJo
software version 10.7 (Tree Star, Ashland, OR). The cells were gated through
forward scatter (FSC) and side scatter (SSC) and then analyzed for Annexin V and
PI ﬂuorescence. Alternatively, cells were analyzed for TMRE ﬂuorescence.
Western blot and protein capillary electrophoresis. For co-IP experiments, cells
were lysed in a lysis buffer, containing 100 mM NaCl, 50 mM Tris-HCl, 0.5% NP40, and 1× protease and phosphatase inhibitor cocktail (Thermo Fisher, 78440).
Cell lysates were incubated with IgG or speciﬁc antibodies conjugated to Dynabeads™ Protein G for Immunoprecipitation (Thermo Fisher, 10004D) over night at
4 °C. For standard western blot and capillary electrophoresis, cells were lysed
directly in the laemmli buffer (Biorad) containing 1× protease and phosphatase
inhibitor cocktail (Thermo Fisher, 78440). Samples were run on a 4−12% SDS
PAGE gel (Invitrogen, NP0321BOX), the proteins were transferred to a PVDF
membrane, and the membrane was blocked with 5% BSA in TBST (0.1% Tween20)
and probed with target antibodies. The western blots were acquired by using the
Azure (C300) imaging system (Azure Biosystems). Capillary electrophoresis was
performed on the Wes instrument according to the manufacturer’s instructions
(ProteinSimple, San Jose, CA; SM-W004). For standard western blot the primary
antibodies used: rabbit anti-PARP (Cell Signaling Technology (CST) 9532; 1:500);
rabbit anti-cCP9 (CST 7237; 1:500); rabbit anti-cCP3 (CST 9665; 1:500); rabbit
anti-USP9x (CST 5751; 1:500); rabbit anti-Bcl-xL (CST 2764; 1:500); rabbit antiBcl-2 (CST 4223; 1:500); rabbit anti-Mcl-1 (CST 5453; 1:500); rabbit anti-CPT1A
(CST 12252; 1:500); mouse anti-Noxa (Calbiochem OP180, clone 114C307; 1:500);
rabbit anti-BIM (CST 2933; 1:500); mouse anti-β-actin (Sigma Aldrich A1978,
clone AC15; 1:8,000); rabbit anti-Aurora A/AIK (1G4) (CST 4718; 1:500); rabbit
anti-p-Aurora A (Thr288) (CST 3079; 1:500); rabbit anti-Myc (CST 13987; 1:500);
and rabbit anti-GSK-3β (27C10) (CST 9315; 1:500). The secondary antibodies were
used: anti-rabbit IgG (H + L) secondary antibody, HRP (Thermo Fisher 31460; 1:
3000) and anti-mouse IgG (H + L) secondary antibody, HRP(Thermo Fisher
31460; 1: 3000). For protein capillary electrophoresis the primary antibodies used
rabbit anti-HK2 (CST 2106, 1:25); rabbit anti-Glut1 (CST 12939; 1:25); rabbit antiLDHA (CST 3582, 1:400); rabbit anti-PGC1α (Novus Biologicals NBP1-04676,
1:25), rabbit anti-c-Myc (CST 13987, 1:25); mouse anti-Bcl-2 (R&D System
MAB827, 1:25); rabbit anti-ATF4 (CST 11815; 1:25); rabbit anti-Vinculin (Abcam
ab129002, 1:500); rabbit anti-Aurora A/AIK (1G4) (CST 4718; 1:500); rabbit antiGSK-3β (27C10) (CST 9315; 1:25), and rabbit anti-phospho-GSK-3β (Ser9) (CST
5558S; 1:25). The secondary antibodies were used with the manufacturer’s
instructions: Anti-Rabbit Secondary HRP Antibody (ProteinSimple 042-206) and
Anti-Mouse Secondary HRP Antibody (ProteinSimple 042-205).
Site directed mutagenesis. HA-Aurora-D274N constructs was generated by
using QuikChange II XL Site-Directed Mutagenesis Kit (Cat# 200521) (Agilent,
Santa Clara, CA) in accordance with the accompanied instructions manual. Primer
sequences are in the Supplementary Table 1.
Real-time PCR analysis. Total RNA was isolated using miRNAeasy Mini Kit
(QIAGEN 217004) and reverse-transcribed to cDNA using cDNA synthesis kit
(Quantabio 101414-106). The cDNA was ampliﬁed using power SYBR green RTPCR reagents kit (Quantabio 101414-276). The reaction was run at 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s, on
a qPCR Instrument (Quantabio). All RT-PCR was performed in quadruplicate and
the average fold changes were calculated based on 18S in the threshold cycle (Cq).
Primer sequences are in the Supplementary Table 1.
Liquid chromatography and mass spectrometry (LC/MS) and isotope tracing.
LC/MS was performed as described in refs. 43,44. Brieﬂy, cells were seeded in six-well
plates and were extracted by methanol/water/chloroform (600 μL/300 μL/400 μL),
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containing an internal standard (Metabolomics Amino Acid Mix Standard, MSKA2-1.2, Cambridge Isotope Laboratories) for polar and non-polar metabolite
extraction. Two layers were separated by drying under nitrogen, the lipid fraction
(non-polar) was dissolved in a mixture of acetonitrile, 2-propanol, and water
(65:30:5, v/v/v), and the water was used for the solubilization of the polar fraction.
Liquid chromatography–high-resolution mass spectrometry (LC/HRMS) was utilized for the analysis of the two fractions. With regards to the isotope tracing
experiments, the GBM cells were exposed to DMEM devoid of nutrients (Thermo
Fisher, A1443001) for 1 h. After that, the GBM cells were cultured in DMEM,
containing either 25 mM (U-13C6) D-Glucose (Cambridge Isotope Laboratories,
Inc), 4 mM (U-13C5) L-Glutamine (Cambridge Isotope Laboratories, Inc), or
100 µM (U-13C16) palmitic acid (Cambridge Isotope Laboratories, Inc) for 24 h in
the presence of 1.5% dialyzed FBS (Thermo Fisher, A3382001). Polar metabolites
were analyzed by Metabolomics Core Facility at Weil Cornell (New York).
Chromatin immunoprecipitation (CHIP) RT-PCR, CHIP-sequencing, and
ATAC-sequencing. Enzymatic CHIP assays were performed in accordance with
the accompanied instructions manual (SimpleChIP® Enzymatic Chromatin IP Kit,
CST 9003). Chromatin immunoprecipitation were incubated with H3K27ac antibody (CST 4535, 10 μL/sample), Myc antibody (CST 13987, 10 μL/sample), or
Rabbit IgG antibody (CST 2729, 1 μL/sample). CHIP H3K27ac or Myc were
submitted for library preparation followed by next-generation sequencing (Illumina HiSeQ 4000 instrument; single read 50 bp (SR50)) (Genewiz, New Jersey).
For ATAC-sequencing, cells were extracted and library preparation was performed
according to the instructions provided in the ATAC-Seq Kit (Active Motif 53150).
Sequencing data were analyzed by Galaxy software (https://usegalaxy.org/) or
basepair software (https://www.basepairtech.com/) and were mapped to the human
genome (hg38), using bowtie. The raw sequences and bigwig ﬁles for ATACsequencing and CHIP-sequencing are deposited in GEO: GSE161572 and
GSE161573, respectively. Primer sequences are in the Supplementary Table 1.
Electron microscopy. For ﬁxation, glioblastoma cells were incubated with 2.5%
glutaraldehyde in Cacodylate buffer for 60 min at RT. One percent of osmium
tetroxide was used for extended ﬁxation in the same buffer. For the embedding
process ALx-112 (Ladd Research Industries, Inc.) and Embed-812 (EMS, Fort
Washington, PA) were used. Tissue sections were derived from the MT-PowerTrome XL ultramicrotome (60 nm) followed by staining with Uranyl acetate and
lead citrate. Examination of the section was performed on the JEOL JEM-1200 EXII
electron microscope. Recorded images were derived from the ORCA-HR digital
camera (Hamamatsu).
Transfections. Cells were seeded in a 12 well plate with density 5 × 104 cells per
well one day prior to transfection. For siRNA transfection experiments, cells were
performed with Lipofectamine RNAiMAX (Invitrogen, 13778075) according to
manufacturers’ instructions. Non-targeting siRNA pool (D-001810-10-20);
AURKA pool siRNA (L-003545-01-0005); AURKA-2 siRNA (J-003545-27-0005);
AURKA-4 siRNA (J-003545-29-0005); PGC1α siRNA (L-005111-00-0005), and
CPT1A siRNA (L-009749-00-0005) were purchased from Dharmacon. Myc-1
siRNA (CST 6341) and Myc-2 siRNA (CST 6552) were purchased from Cell Signaling. For ectopically expressed experiments, cells were transfected using Lipofectamine 3000 (Invitrogen). pD40-His/V5-c-Myc (#45597) and pD40-His/V5-cMycT58A (#45598) constructs were purchased from Addgene (Watertown, MA).
For knock down and knock out experiments, cells were infected in the presence of
8 µg/mL polybrene (Santa Cruz Biotechnology) and were selected with puromycin
(Santa Cruz Biotechnology). ARK-1 shRNA (h) Lentiviral Particles (sc-29731-V)
was purchased were purchased from Santa Cruz Biotech (Santa Cruz, CA).
AURKA sgRNA CRISPR Lentivirus set (human) (Cat# 128661110101) was purchased from Applied Biological Materials. Adeno CMV Null Adenovirus (AdCMV-Null 1300) and c-Myc Adenovirus (Ad-c-Myc 1285) were purchased from
Vector Biolabs (Malvern, PA) and were infected according to the manufactures’
instructions.
Microarray and subsequent gene set enrichment (GSEA) analysis. The
experiment is comprised of four Human Gene 2.0 ST arrays, comparing between
the control and treated cells. For normalization of the microarrays (performed at
the same time), the Robust Multiarray Average (RMA) algorithm along with a CDF
(Chip Deﬁnition File), which provides the unique Entrez Gene identiﬁers, were
used. The experiments used in this study for GBM22 and GBM22AR were
deposited at GEO: GSE152612.
Extracellular ﬂux analysis. Oxygen consumption rate (OCR) and extracellular
acidiﬁcation rate (ECAR) were measured with a Seahorse XFe24 Analyzer (Agilent,
Santa Clara, CA) or a Seahorse XFp Analyzer (Agilent, CA). Cells were seeded in
XFe24 cell culture microplates (Agilent, CA) at 3 × 104 cells/well or in XFp cell
culture microplates at 5 × 103 cells/well in DMEM medium containing 5 mM
glucose, 1 mM pyruvate, and 10% FBS and allowed to attach overnight. Cells were
treated with reagents or corresponding solvents in the medium containing 5 mM
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glucose, 1 mM pyruvate, and 1.5% FBS in the following day. Mitochondrial stress
assay (Agilent, 103015-100) was performed in the Seahorse XF base medium
(Agilent, 102353-100) containing 10 mM glucose, 2 mM glutamine, 1 mM pyruvate. The following compounds were injected in a sequential order: 2 µM oligomycin (OM), 2 µM Carbonyl cyanide-4 (triﬂuoromethoxy) phenylhydrazone
(FCCP), and 0.5 µM rotenone/antimycin (R/A). Glycolysis stress assay (Agilent,
103020-100) was performed in the Seahorse XF base medium containing 1 mM
glutamine. The following compounds were injected in a sequential order: 10 mM
glucose (G), 1 µM oligomycin (O), and 50 mM 2-DG.
Subcutaneous xenograft model. 1 × 106 patient-derived xenograft GBM12, GBM43
cells, or colon carcinoma HCT116 cells were implanted subcutaneously into the ﬂanks
of 6−8 weeks old SCID/SHO mice. Intraperitoneal treatments and tumor measurements were performed three times a week. Drugs were dissolved in a mixture of drug,
Kolliphor® EL (Sigma, C5135-500G), Ethyl Alcohol (Pharmco-Aaper, 200 Proof), and
PBS at the ratio: 10:32:8:50 (v/v/v). Drug doses used: 30 mg/kg alisertib, 20 mg/kg
etomoxir or 5 mg/kg GTPP. Tumor size was measured with a caliper and was calculated as (length × width2)/2. Mice body weights were monitored at each time point.
Orthotopic glioblastoma PDX model. GBM12 and GBM22 were intracranially
injected 30 × 104 cells at (3 mm lateral, 1 mm anterior of the bregma, and 3 mm
down). Intraperitoneal treatments were performed three times a week until the
animals become moribund or neurological deﬁcits (retardation, paresis, lethargy,
seizures, hyperactivity). To calculate p-values (signiﬁcant p < 0.05), the Log-rank
test was used. Survival is indicated by Kaplan−Meier survival fractions (plot survival versus time).
In situ proximity ligation assay (PLA). Cells were seeded with density 1,500 cells/
well on the eight well chamber Nunc® Lab-Tek® Chamber Slide™ system (Sigma,
C7182-1PAK) overnight. Cells were ﬁxed in 4% formaldehyde (Thermo Fisher,
28908) for 10 min at RT, permeablized with 0.1% Triton in PBS for 15 min at RT,
and blocked with the manufacturer’s blocking agent (Duolink™ In Situ Red Starter
Kit Mouse/Rabbit (Sigma, Cat# DUO92101-1KT) for 1 h followed by incubation
with paired primary antibodies: Aurora kinase A (1F8) Mouse mAb (CST 12100;
1:100), Myc Rabbit Ab (CST 13987; 1:100); and GSK-3β Rabbit Ab (27C10) (CST
9315; 1:100). PLA detection was performed in accordance with the accompanied
instructions manual. Images were captured by Axio Observer 7 microscope (Zeiss)
using 10× objective (0.45 N.A) Image analyses were performed with custom Matlab
scripts (ver. R2019b).
TUNEL and Ki67 staining. Following rehydration of the parafﬁn-embedded sections, the slides were exposed to proteinase K (Agilent DAKO) for 5 min at 37 °C.
The tissue sections were incubated in TUNEL reaction mixture for 1 h at 37 °C and
followed by termination, using the POD solution for 30 min at 37 °C. The chromogen diaminobenzidine was utilized to develop the TUNEL staining, while
hematoxylin was employed as a non-speciﬁc nuclear stain. Prior to Ki67 staining,
slides were incubated in citric acid buffer and heated (antigen retrieval). Thereafter,
primary antibody labeling with Ki67 (Dako GA626) was performed for 1.5 h at RT.
A secondary antibody horse anti mouse IgG (1:200) was used for 30 min followed
by labeling with ABC-Peroxidase solution (1:50) for 30 min at RT.
Statistics and reproducibility. Statistical signiﬁcance was assessed by a two-tailed
student’s t-test or ANOVA (for multiple comparisons) using Prism version 5.04
(GraphPad, La Jolla, CA). A p ≤ 0.05 was considered statistically signiﬁcant.
CompuSyn software (ComboSyn, Inc., Paramus, NJ) was used for the drug combination analysis including the calculation of the combination index (CI). CI < 1
was considered as synergistic, CI = 1 as an additive, and CI > 1 as antagonistic. All
in vitro experiments were performed independently at least twice with similar
results.
Study approval. All procedures were done in accordance with Animal Welfare
Regulations and approved by the Institutional Animal Care and Use Committee at
the Columbia University Medical Center (AC-AABC6505 and AC-AAAV7451).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The raw and processed ATAC-sequencing, CHIP-sequencing, and microarray data
generated in this study have been deposited in the Gene Expression Omnibus (GEO),
https://www.ncbi.nlm.nih.gov/geo/, under accession code GSE161572, GSE161573, and
GSE152612 respectively. Source data are provided with this paper.

Code availability
Source code is provided with this paper at https://github.com/scappell/
Cell_tracking. Source data are provided with this paper.
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